Agios Pharmaceuticals (AGIO) vs Structure Therapeutics (GPCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Structure Therapeutics (GPCR) has outperformed Agios Pharmaceuticals (AGIO) over the past year, losing 6.1% versus a loss of 22.2%. Agios Pharmaceuticals is the larger company by market cap ($1.91 billion vs $1.82 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | GPCR |
|---|---|---|
| Share price | $31.99 | $25.58 |
| Market cap | $1.91B | $1.82B |
| 1-day change | +0.63% | -4.12% |
| YTD return | +16.79% | -61.64% |
| 1-year return | -22.22% | -6.12% |
| 5-year return | -31.31% | — |
| EPS (TTM) | $-7.03 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.00 | $94.90 |
| 52-week low | $22.24 | $25.09 |
| Distance from 52-week high | -30.46% | -73.05% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +43.79% | +313.53% |
| Average volume | 1.05M | 957.51K |
| Shares outstanding | 59.70M | 71.31M |
| Employees | 539 | 281 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GPCR has outperformed AGIO by 16.1 percentage points over the past year.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
AGIO vs GPCR FAQ
Which is bigger, Agios Pharmaceuticals or Structure Therapeutics?
Agios Pharmaceuticals (AGIO) is larger, with a market capitalization of $1.91B compared with $1.82B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, AGIO or GPCR?
GPCR returned -6.12% over the past 12 months, compared with -22.22% for AGIO (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Structure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.